JP6405319B2 - 乳癌予知のための画像分析 - Google Patents

乳癌予知のための画像分析 Download PDF

Info

Publication number
JP6405319B2
JP6405319B2 JP2015550033A JP2015550033A JP6405319B2 JP 6405319 B2 JP6405319 B2 JP 6405319B2 JP 2015550033 A JP2015550033 A JP 2015550033A JP 2015550033 A JP2015550033 A JP 2015550033A JP 6405319 B2 JP6405319 B2 JP 6405319B2
Authority
JP
Japan
Prior art keywords
score
heterogeneity
her2
breast cancer
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015550033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503167A5 (enExample
JP2016503167A (ja
Inventor
チュッカ,シュリニヴァス
サルカル,アニンディヤ
シェンプ,クリスタル
セルテル,オルケイ
スィン,シャリニ
タブス,レイモンド
ワリング,ポール・マイケル
ヴィック,ニコラウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of JP2016503167A publication Critical patent/JP2016503167A/ja
Publication of JP2016503167A5 publication Critical patent/JP2016503167A5/ja
Application granted granted Critical
Publication of JP6405319B2 publication Critical patent/JP6405319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00ICT specially adapted for the handling or processing of medical images
    • G16H30/20ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
JP2015550033A 2012-12-28 2013-12-19 乳癌予知のための画像分析 Active JP6405319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747148P 2012-12-28 2012-12-28
US61/747,148 2012-12-28
PCT/EP2013/077295 WO2014102130A1 (en) 2012-12-28 2013-12-19 Image analysis for breast cancer prognosis

Publications (3)

Publication Number Publication Date
JP2016503167A JP2016503167A (ja) 2016-02-01
JP2016503167A5 JP2016503167A5 (enExample) 2016-12-28
JP6405319B2 true JP6405319B2 (ja) 2018-10-17

Family

ID=49917058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550033A Active JP6405319B2 (ja) 2012-12-28 2013-12-19 乳癌予知のための画像分析

Country Status (8)

Country Link
US (2) US11211167B2 (enExample)
EP (1) EP2939026B1 (enExample)
JP (1) JP6405319B2 (enExample)
AU (1) AU2013369439B2 (enExample)
CA (1) CA2890964C (enExample)
DK (1) DK2939026T3 (enExample)
ES (1) ES2639559T3 (enExample)
WO (1) WO2014102130A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508854A1 (en) 2010-04-27 2019-07-10 The Regents of The University of California Cancer biomarkers and methods of use thereof
US20140323325A1 (en) * 2013-03-06 2014-10-30 Marc Beal Molecular imaging and related methods
WO2015189264A1 (en) 2014-06-10 2015-12-17 Ventana Medical Systems, Inc. Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
EP3227833B1 (en) * 2014-12-03 2024-12-25 Ventana Medical Systems, Inc. Systems and methods for early-stage cancer prognosis
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US9613254B1 (en) 2015-09-30 2017-04-04 General Electric Company Quantitative in situ characterization of heterogeneity in biological samples
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
EP3555622B1 (en) * 2016-12-19 2023-02-22 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
CN110678934A (zh) * 2017-06-02 2020-01-10 皇家飞利浦有限公司 医学图像中的病变的定量方面
CN107271671A (zh) * 2017-06-05 2017-10-20 龚畅 一种预测er(+)乳腺癌新辅助化疗效果的试剂盒和系统
US10586376B2 (en) * 2017-06-13 2020-03-10 Optrascan, Inc. Automated method of predicting efficacy of immunotherapy approaches
RU2664671C1 (ru) * 2017-07-28 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ прогноза рака молочной железы
CN111448584B (zh) 2017-12-05 2023-09-26 文塔纳医疗系统公司 计算肿瘤空间和标记间异质性的方法
CN111448569B (zh) * 2017-12-06 2023-09-26 文塔纳医疗系统公司 存储和检索数字病理学分析结果的方法
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
CN111417958B (zh) 2017-12-07 2025-02-25 文塔纳医疗系统公司 用于生物图像中的联合细胞和区域分类的深度学习系统和方法
EP3729369A2 (en) 2017-12-24 2020-10-28 Ventana Medical Systems, Inc. Computational pathology approach for retrospective analysis of tissue-based companion diagnostic driven clinical trial studies
US11621058B2 (en) * 2018-02-08 2023-04-04 Ohio State Innovation Foundation Synthetic IHC-stained digital sides generated using artificial neural networks
WO2019197509A1 (en) 2018-04-13 2019-10-17 Ventana Medical Systems, Inc. Systems for cell shape estimation
EP3830742B1 (en) 2018-07-27 2025-02-26 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
EP3844771A1 (en) 2018-08-31 2021-07-07 Ventana Medical Systems, Inc. Contextually adaptive digital pathology interface
EP3850368A4 (en) * 2018-09-14 2022-11-23 Prelude Corporation PROCEDURE FOR SELECTING THE TREATMENT OF SUBJECTS AT RISK FOR INVASIVE BREAST CANCER
WO2020081343A1 (en) 2018-10-15 2020-04-23 Ventana Medical Systems, Inc. Systems and methods for cell classification
CN120148643A (zh) * 2018-12-19 2025-06-13 匹兹堡大学高等教育联邦体系 用于原位或体外多参数细胞和亚细胞成像数据的计算系统病理学空间分析平台
EP3924722B1 (en) 2019-02-13 2025-09-17 Ventana Medical Systems, Inc. Systems and methods for computing the contributions of autofluorescence in multichannel images
US12175660B2 (en) * 2019-02-15 2024-12-24 Konica Minolta, Inc. Method, device, and program for obtaining information from tissue sections for pathological diagnosis support
US11726757B2 (en) * 2019-08-14 2023-08-15 Nvidia Corporation Processor for performing dynamic programming according to an instruction, and a method for configuring a processor for dynamic programming via an instruction
CN114270174B (zh) 2019-08-28 2026-03-10 文塔纳医疗系统公司 使用振动光谱对生物标志物表达进行无标记评估
EP4028990A1 (en) * 2019-09-09 2022-07-20 PAIGE.AI, Inc. Systems and methods for processing images of slides to infer biomarkers
CN110853022B (zh) 2019-11-14 2020-11-06 腾讯科技(深圳)有限公司 病理切片图像的处理方法、装置、系统及存储介质
CN114945941B (zh) 2020-01-19 2025-11-28 文塔纳医疗系统公司 用于支持肿瘤检测和分析的非肿瘤分割
EP4104093A1 (en) 2020-02-11 2022-12-21 Ventana Medical Systems, Inc. Federated learning system for training machine learning algorithms and maintaining patient privacy
US20210287801A1 (en) * 2020-03-11 2021-09-16 Biosyntagma, Inc. Method for predicting disease state, therapeutic response, and outcomes by spatial biomarkers
WO2021188617A1 (en) * 2020-03-18 2021-09-23 Sanofi Systems and methods for predicting expression levels
US11508066B2 (en) * 2020-08-13 2022-11-22 PAIGE.AI, Inc. Systems and methods to process electronic images for continuous biomarker prediction
DE102020211271A1 (de) * 2020-09-08 2022-03-10 Siemens Healthcare Gmbh Erzeugung eines Biomarkers quantifizierend eine räumliche Homogenität einer medizinischen Parameterkarte
CN116710131A (zh) * 2020-09-22 2023-09-05 文塔纳医疗系统公司 使用表皮调节素和双调蛋白来预测对表皮生长因子受体定向疗法的反应
CN112801939B (zh) * 2020-12-31 2022-07-22 杭州迪英加科技有限公司 一种用于提高病理图像ki67指标准确性的方法
WO2022264545A1 (ja) * 2021-06-17 2022-12-22 コニカミノルタ株式会社 定量方法および標識方法
CN113970638B (zh) * 2021-10-24 2023-02-03 清华大学 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用
WO2024035612A1 (en) * 2022-08-08 2024-02-15 Ventana Medical Systems, Inc. System and method for quantification of digitized pathology slides
WO2024178422A1 (en) * 2023-02-24 2024-08-29 Ohio State Innovation Foundation Novel image-based metrics of her2 heterogeneity
WO2024259271A2 (en) * 2023-06-15 2024-12-19 New York University Systems, methods and computer-accessible medium for determining and/or analysing cancer outcome(s) and/or treatment responses
WO2025014787A1 (en) * 2023-07-07 2025-01-16 Ventana Medical Systems, Inc. Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells
WO2025106811A1 (en) * 2023-11-15 2025-05-22 4D Path Inc. Systems and methods for image-based disease characterization
KR20250156974A (ko) 2024-04-26 2025-11-04 사회복지법인 삼성생명공익재단 딥러닝 모델을 이용한 종양 미세환경 예측 방법 및 분석장치
TWI900356B (zh) * 2024-12-03 2025-10-01 國立中央大學 建立組織微陣列影像模型以及使用該模型判定組織型態的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US20050136549A1 (en) 2003-10-30 2005-06-23 Bioimagene, Inc. Method and system for automatically determining diagnostic saliency of digital images
US8787651B2 (en) * 2010-09-28 2014-07-22 Flagship Biosciences, LLC Methods for feature analysis on consecutive tissue sections
US9286672B2 (en) * 2012-01-10 2016-03-15 Rutgers, The State University Of New Jersey Integrated multivariate image-based method for disease outcome predicition
JP2013200287A (ja) 2012-03-26 2013-10-03 Kawasaki Gakuen Ki−67インデックス算定二重染色法を用いた陽性率測定方法

Also Published As

Publication number Publication date
US20150347702A1 (en) 2015-12-03
US11211167B2 (en) 2021-12-28
AU2013369439B2 (en) 2019-01-17
US20220051804A1 (en) 2022-02-17
WO2014102130A1 (en) 2014-07-03
CA2890964A1 (en) 2014-07-03
DK2939026T3 (en) 2017-09-11
CA2890964C (en) 2023-07-25
JP2016503167A (ja) 2016-02-01
ES2639559T3 (es) 2017-10-27
AU2013369439A1 (en) 2015-05-28
EP2939026A1 (en) 2015-11-04
EP2939026B1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
JP6405319B2 (ja) 乳癌予知のための画像分析
Potts et al. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
Klauschen et al. Standardized Ki67 diagnostics using automated scoring—clinical validation in the GeparTrio breast cancer study
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
Focke et al. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods
Niikura et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups
Varga et al. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Sun et al. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
Zbytek et al. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score
Shafi et al. Integrating and validating automated digital imaging analysis of estrogen receptor immunohistochemistry in a fully digital workflow for clinical use
Zhao et al. Associations of estrogen receptor, progesterone receptor, human epidemic growth factor receptor-2 and Ki-67 with ultrasound signs and prognosis of breast cancer patients
Kim et al. Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers
Sode et al. Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2‐low breast cancer
Qi et al. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
Feng et al. Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer
Fulawka et al. Proliferation index evaluation in breast cancer using ImageJ and ImmunoRatio applications
Jonmarker Jaraj et al. Intra-and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer
Cho et al. The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value
van Kempen et al. Monitoring immunohistochemical staining variations using artificial intelligence on standardized controls
Di Caro et al. A novel liquid biopsy assay for detection of ERBB2 (HER2) amplification in circulating tumor cells (CTCs)
Singh et al. Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers
Tobin et al. Automated image analysis of cyclin D1 protein expression in invasive lobular breast carcinoma provides independent prognostic information
Jing et al. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer
Nassar et al. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens
Wang et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180914

R150 Certificate of patent or registration of utility model

Ref document number: 6405319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250